Evaluation of NMES Therapy for Pain Relief Associated With Knee Osteoarthritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

64 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-04-20

Study Completion Date

2021-03-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A roll-over study of the current CM-2019 trial to assess the same preplanned outcomes of CM-2019 at 14 weeks.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of a Home-based NMES Therapy for Knee Osteoarthritis Pain

NCT04128618

Knee Osteoarthritis

COMPLETED NA

Evaluation of NMES for Reducing Pain and Improving Functional Outcomes in Knee OA Patients

NCT03980964

Knee Osteoarthritis Knee Pain Chronic Knee Arthritis

COMPLETED NA

Exercise and Muscle Stimulation in Patients With Knee Osteoarthritis

NCT01320904

Osteoarthritis, Knee Self Stimulation Exercise Addiction

COMPLETED NA

Influence of Noxious Electrical Stimulation on Chronic Pain From Knee Osteoarthritis

NCT04628013

Knee Osteoarthritis

COMPLETED NA

The Efficacy of Exercise and Alternative Applications of NMES on Pain and Function in Patients With Knee OA

NCT03571698

Knee Osteoarthritis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This roll-over study is designed as a 14-week treatment continuation from CM-2019 (parent study), a randomized, sham controlled, double-blind, multi-center study trial to evaluate the efficacy of CyMedica Orthopedics e-vive™ system, a multifunctional electrotherapy device providing neuromuscular electrical stimulation (NMES) as an adjunctive therapy for pain relief and accelerating functional recovery in patients with knee osteoarthritis. This follow-up trial will include subjects who have been randomized into the CM-2019 trial. Subjects will be enrolled into the appropriate treatment group based upon the treatment received in the parent study. It is hypothesized that the continued use of CyMedica e-vive NMES may provide additional pain relief and improved knee function for an additional 14 weeks compared to sham.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Knee Osteoarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized, sham-controlled, double-blind, multi-center

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active NMES

Group Type EXPERIMENTAL

Home-based Neuromuscular Electrical Stimulation (NMES) therapy

Intervention Type DEVICE

A home-based NMES treatment applied by the subjects daily

Modified NMES sham

Group Type SHAM_COMPARATOR

Home-based Neuromuscular Electrical Stimulation (NMES) therapy

Intervention Type DEVICE

A home-based NMES treatment applied by the subjects daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Home-based Neuromuscular Electrical Stimulation (NMES) therapy

A home-based NMES treatment applied by the subjects daily

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject must provide a signed informed consent for CM-2019R. The subject will be provided with a copy of the signed Informed Consent upon signature.
2. Currently enrolled in the parent trial CM-2019 or have successfully completed the parent trial within 21 days of enrollment in the roll-over trial.
3. Willing and able to continue parent trial study treatment.
4. Pregnancy test, if it has been \>14 days since completion of the parent trial.
5. Subject must continue to be willing to refrain from receiving knee intra-articular injections of steroids, knee intra-articular injections of hyaluronic acid, opioids, and analgesics (except for acetaminophen up to 3000 mg/day or an equivalent) for the duration of the study.
6. Subject must continue to be willing to take acetaminophen (up to 3000 mg/day) or an equivalent as pain medication for the duration of the study.
7. Subject must continue to be willing to stop taking any pain medications 24 hours prior any scheduled study visit.
8. Subject must continue to be willing to stop receiving knee physical therapy of the target knee for the duration of the study.
9. Subject must continue be willing to stop wearing any knee unloader brace of the target knee for the duration of the study.
10. Subjects must be willing and able to comply with all study procedures for the duration of the clinical study

Exclusion Criteria

1. Subjects with a new diagnosis of inflammatory arthritis (knee rheumatoid arthritis, active gout, knee joint infection, Lyme disease, SLE, etc.) since parent trial enrollment.
2. Subjects with a new diagnosis of severe neuropathy condition and under medication for treatment of the condition since parent trial enrollment.
3. Subjects with a new diagnosis of fibromyalgia since parent trial enrollment.
4. Subjects who have had an injury or an acute traumatic injury to the target knee since parent trial enrollment.
5. Subject must NOT have had arthroscopy of the target knee since parent trial enrollment.
6. Subjects who have had treatment of the target knee with intra-articular injections of steroids since parent trial enrollment. Subjects who have had intra-articular injections of hyaluronic acid since parent trial enrollment.
7. Subjects who have a scheduled surgery on the target knee within the study period. (Subjects that are contemplating the surgery can be included.)
8. Subjects who have used electrotherapy or acupuncture for OA of the target knee since parent trial enrollment year.
9. Subjects who have had implanted electrical devices since parent trial enrollment (cardiac pacemakers, deep brain stimulators, implantable cardiac defibrillators).
10. Subjects with a current new malignancy or who have received treatment for malignancy since parent trial enrollment, with the exception of resected basal cell carcinoma and squamous cell carcinoma of the skin.
11. Subjects with a new skin breakdown or infection in the area where the study device will be placed (quadriceps of the target knee).
12. Subjects with any newly reported chronic conditions (e.g., diabetes, hypertension, congestive heart failure, etc.) or that have not been well-controlled during the parent trial.
13. Subjects who have any new litigation for worker's compensation.
14. Subjects with any new condition, in the opinion of the Investigator that might interfere with the evaluation of the study objectives.
15. Subjects who are pregnant.
16. Subject who enrolled in any new clinical study from the last day of treatment in the parent trial that required the use of an investigational device, drug or biologic.

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes